Wegovy (Semaglutide) and Mounjaro (Tirzepatide) access in Cheshire and Merseyside
Obesity is one of the leading causes of serious health conditions such as cardiovascular disease, diabetes and cancer – and costs the NHS £6.5 billion a year. There were more than one million admissions to NHS hospitals in 2019-20 where obesity was a factor.
Semaglutide (Wegovy) is a weight loss drug that was approved by NICE in the UK on 4 September 2023. Tirzepatide (Mounjaro) has since been approved by NICE on 23 December 2024. Read more about Wegovy (Semaglutide) and Mounjaro (Tirzepatide) access in Cheshire and Merseyside.